Skip to Content

Bulent Ozpolat, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, UTMDACC, Houston, TX

Education & Training

Degree-Granting Education

1999 UT M D Anderson Cancer Center Graduate School of Biomedical Science (GSBS), Houston, TX, PHD, Immunology
1989 Dokuz Eylul University School of Medicine, Izmir, Turkey, MD, Medicine


Academic Appointments

Research Assistant, Department of Biochemistry, Pamukkale University, Denizli, Turkey, 1/1993
Graduate Research Assistant, Department of Biochemistry, Health Science Center-Dokuz Eylul University Medical School, Izmir, Turkey, 1/1990-1/1992

Other Appointments/Responsibilities

Staff Physician, Emergency Service, Izmir State Hospital, Izmir, Turkey, 1/1989-1/1992

Honors and Awards

2008 Susan G. Komen Career Development Award, Susan G. Komen
2003 Research Grant Award, Ladies Leukemia League
1999 John P. McGovern Graduate Student Award for Scientific Achievement, The University of Texas-Houston M. D. Anderson Cancer Center Graduate School of Biomedical Sciences
1999 Nomination for Outstanding Ph.D. Dissertation award, The University of Texas-Houston M. D. Anderson Cancer Center
1993 State Merit Scholarship to Pursue Ph.D., The National Higher Educational Board of Turkey

Selected Publications

Peer-Reviewed Original Research Articles

1. Ozpolat B. Modulation of Autophagy by polyphenolic compounds as a Potential Therapeutic Strategy for Cancer. Cell Death & Disease. In Press. PMCID: PMCN/A.
2. Olmez I, Shen W, McDonald H, Ozpolat B. Dedifferentiation of Patient-derived glioblastoma multiforme cell lines results in a cancer stem cell like state with mitogen-independent growth. J Cell Mol Med 19(6):1262-72, 6/2015. e-Pub 3/19/2015. PMCID: PMC4459842.
3. Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Fuentes-Mattei E, Deng D, Hwang RF, Wang H, Ivan C, Garza RJ, Cohen E, Gao H, Armaiz-Pena GN, Del C Monroig-Bosque P, Philip B, Rashed MH, Aslan B, Erdogan MA, Gutierrez-Puente Y, Ozpolat B, Reuben JM, Sood AK, Logsdon C, Lopez-Berestein G. Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin-Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther 13(11):2583-94, 11/2014. e-Pub 9/5/2014. PMCID: PMC4221441.
4. Ashour AA, Gurbuz N, Alpay SN, Abdel-Aziz AA, Mansour AM, Huo L, Ozpolat B. Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion. J Cell Mol Med 18(11):2235-51, 11/2014. e-Pub 9/12/2014. PMCID: PMC4224557.
5. Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, Baggerly KA, Sood AK. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin Cancer Res 20(12):3280-8, 6/15/2014. e-Pub 4/22/2014. PMCID: PMC4062703.
6. Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep 7(2):488-500, 4/24/2014. e-Pub 4/3/2014. PMCID: PMC4038960.
7. Devkota AK, Warthaka M, Edupuganti R, Tavares CD, Johnson WH, Ozpolat B, Cho EJ, Dalby KN. High-Throughput Screens for eEF-2 Kinase. J Biomol Screen 19(3):445-52, 3/2014. e-Pub 9/27/2013. PMID: 24078616.
8. Ashour AA, Abdel-Aziz AA, Mansour AM, Alpay SN, Huo L, Ozpolat B. Targeting elongation factor-2 kinase (eEF-2K) induces apoptosis in human pancreatic cancer cells. Apoptosis 19(1):241-58, 1/2014. e-Pub 11/2013. PMID: 24193916.
9. Gurbuz N, Ashour AA, Alpay SN, Ozpolat B. Down-regulation of 5-HT1B and 5-HT1D receptors inhibits proliferation, clonogenicity and invasion of human pancreatic cancer cells. PLoS One 9(8):e105245, 2014. e-Pub 8/29/2014. PMCID: PMC4149367.
10. Hasima N, Ozpolat B. Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer. Cell Death Dis 5:e1509, 2014. e-Pub 11/2014. PMCID: PMC4260725.
11. Aslan B, Ozpolat B, Sood AK, Lopez-Berestein G. Nanotechnology in cancer therapy. J Drug Target 21(10):904-13, 12/2013. e-Pub 9/2013. PMCID: PMCN/A.
12. Tekedereli I, Alpay SN, Akar U, Yuca E, Ayugo-Rodriguez C, Han HD, Sood AK, Lopez-Berestein G, Ozpolat B. Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (-) and ER (+) Breast Cancer. Molecular Ther Nucleic Acids 2, Sept. 10, 2013, 9/2013. PMCID: PMC4028016.
13. Jin Y, Qu S, Tesikova M, Wang L, Kristian A, Mćlandsmo GM, Kong H, Zhang T, Jerónimo C, Teixeira MR, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood AK, Lopez-Berestein G, Danielsen HE, Ozpolat B, Saatcioglu F. Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proc Natl Acad Sci USA 110(28). e-Pub 6/2013. PMCID: PMC3710885.
14. Yenigun VB, Ozpolat B, Kose GT. Response of CD44/CD24 Low Breast Cancer Stem/Progenitor Cells to Tamoxifen and Doxorubicin Induced Autophagy. International Journal of Molecular Medicine 31(6):1477-1483, 6/2013. e-Pub 4/2013. PMCID: PMCN/A.
15. Shao L, Tekedereli I, Wang J, Yuca E, Sood A, Lopez-Berestein G, Ozpolat B*, Ittmann M* (*corresponding authors). Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clinical Cancer Research 18(24). e-Pub 10/2012. PMCID: PMC3525716.
16. Tavares CD, O'Brien JP, Abramczyk O, Devkota AK, Shores KS, Ferguson SB, Kaoud TS, Warthaka M, Marshall KD, Keller KM, Zhang Y, Brodbelt JS, Ozpolat B*, Dalby KN* (*corresonding authors). Calcium/Calmodulin Stimulates the Autophosphorylation of Elongation Factor 2 Kinase on Thr-348 and Ser-500 to Regulate its Activity and Calcium Dependence. Biochemistry. e-Pub 2/2012. PMCID: PMC3401519.
17. Devkota AK, Tavares CD, Warthaka M, Abramczyk O, Marshall KD, Kaoud TS, Gorgulu K, Ozpolat B*, Dalby KN* (*corresponding authors). Investigating the Kinetic Mechanism of Inhibition of Elongation Factor 2 Kinase (eEF-2K) by NH125: Evidence for a Common in vitro Artifact. Biochemistry. e-Pub 2/2012. PMCID: PMC3673019.
18. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupaimoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366(7):610-8, 2/2012. PMCID: PMC3296780.
19. Ozpolat B*, Akar U, Tekedereli, Alapy N, Lopez-Berestein G* (*corresponding authors). PKC Regulates Translation Initiation through PKR and elF2a in Response to Retinoic Acid in Acute Myeloid Leukemia Cells. Leukemia Research and Treatment 2012(2012), 2012. e-Pub 7/2012. PMCID: PMC3505929.
20. Tekedereli I, Alpay SN, Tavares CD, Cobanoglu ZE, Kaoud TS, Sahin I, Sood AK, Lopez-Berestein G, Dalby KN, Ozpolat B. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to Doxorubicin in an orthotopic model of breast cancer. PLoS One 7(7):e41171, 2012. e-Pub 7/2012. PMCID: PMC3401164.
21. Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim HS, Lee JS, Kim SM, Baggerly KA, Ram PT, Deavers MT, Coleman RL, Lopez-Berestein G, Sood AK. Silencing of p130Cas in Ovarian Carcinoma: A Novel Mechanism for Tumor Cell Death. J Natl Cancer Inst 103(21):1596-612, 11/2011. e-Pub 9/2011. PMCID: PMC3206039.
22. Abramczyk O, Tavares CD, Devkota AK, Ryazanov AG, Turk BE, Riggs AF, Ozpolat B*, Dalby KN* (*corresponding authors). Purification and characterization of tagless recombinant human elongation factor 2 kinase (eEF-2K) expressed in Escherichia coli. Protein Expr Purif 79(2), 10/2011. PMCID: PMC21605678.
23. Akar U, Ozpolat B, Mehta K, Lopez-Berestein G, Zhang D, Ueno NT, Hortobagyi GN, Arun B. Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther 9(5):1180-7, 5/2010. e-Pub 4/2010. PMCID: PMCN/A.
24. Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B,. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 6(3). e-Pub 4/2010. PMCID: PMC2914492.
25. Vivas-Mejía PE, Ozpolat B, Chen X, Lopez-Berestein G. Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Int J Cancer 125(2):264-275, 7/2009. e-Pub 2/2009. PMID: 19408305.
26. Ozpolat B, Akar U, Zorrilla-Calancha I, Vivas-Mejia P, Acevedo-Alvarez M, Lopez-Berestein G. Death-Associated Protein 5 (DAP5/p97/NAT1) Contributes to Retinoic Acid-Induced Granulocytic Differentiation and Arsenic Trioxide-Induced Apoptosis in Acute Promyelocytic Leukemia. Apoptosis 13(7):915-28, 7/2008. PMID: 18491231.
27. Akar U, Chaves-Reyes A, Barria M, Tari A, Saungino A, Kondo Y, Kondo S, Arun B, Lopez-Berestein G, Ozpolat B(corresponding author). Silencing of Bcl-2 Expression by Small Interfering RNA Induces Autophagic Cell Death in MCF-7 Breast Cancer Cells. Autophagy 4(5), 4/2008. PMID: 18424910.
28. Ozpolat B, Akar U, Mehta K, Lopez-Berestein G. PKC delta and tissue transglutaminase are novel inhibitors of autophagy in pancreatic cancer cells. Autophagy 3(5):480-3, Sep-Oct, 9/2007. e-Pub 4/2007. PMID: 17507797.
29. Akar U, Ozpolat B (Co-First Authors), Mehta K, Fok J, Kondo Y, Lopez-Berestein G. Tissue transglutaminase inhibits autophagy in pancreatic cancer cells. Mol Cancer Res 5(3):241-9, 3/2007. PMID: 17374730.
30. Ozpolat B, Akar U, Steiner M, Zorrilla-Calancha I, Tirado-Gomez M, Colburn N, Danilenko M, Kornblau S, Berestein GL. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res 5(1):95-108, 1/2007. PMID: 17259349.
31. Jin Y, Qu S, Tesikova M, Wang L, Kristian A, Maelandsmo GM, Kong H, Zhang T, Jeronimo C, Teixeira MR, Tekedereli I, Alpay N, Gorgulu K, Yuca E, Sood A, Lopez-Berestein G, Danielsen HE, Ozpolat B, Saatcioglu F. A molecular circuit integrates androgen and mTOR signaling in prostate cancer. Cancer Cell. Submitted. PMCID: PMCN/A.
32. Tekedereli I, et al. In vivo targeted silencing of Bcl-2 by systemically administered nanolipsomal siRNA inhibits growth of orthotopic breast cancer models. Mol Can Cet Therapeutics. Submitted. PMCID: PMCN/A.
33. Ozpolat BTekedereli I, Akar U, Alpay N, Lopez-Berestein G. PKC delta regulates IF2alpha through PKr in APl during cell differentiation. Leukemia Research & Therapy. Submitted. PMCID: PMCN/A.
34. Ozpolat B, Akar U, Barria M, Lopez-Berestein G. PKCdelta regulates eukaryotic initiation factor eIF2alpha through PKR during retinoic acid-induced myeloid cell differentiation. Leukemia Research. Submitted. PMCID: PMCN/A.
35. Wen, Y, Zand B, Carrell AR, Kang Y, Yuca E, Tekedereli I, Bottsford-Miller J, Stone R, Pradeep S, Wu SY, Pecot CV, Hu W, Ueno NT, Ozpolat B, Coleman RL, Sood AK. Promoting Autophagic Cell Death by Blocking Prolactin in Ovarian Carcinoma. Nature. Submitted. PMCID: PMCN/A.
36. Wang L, Jin Y, Qu S, Kristian A, Maelandsmo GM, Tekedereli I, Alpay N, Gorgulu K, Yuca E, Sood A, Lopez-Berestein G, Riserg B, Waehre H, Danielsen HE, Ozpolat, Saatcioglu F. STAMP2 increases oxidative stress through its ferrireductase activity and is critical for prostate cancer progression. Clinical Cancer Research. Submitted. PMCID: PMCN/A.
37. Tekedereli I, Akar U, Alpay N, Lopez-Berestein G, Sood A, Ozpolat B,. Therapeutic targeting of EF2K by siRNA inhibits tumor growth. Molecular Cancer Therapeutics. Submitted. PMCID: PMCN/A.
38. Tekedereli I, Akar U, Alpay N, Lopez-Berestein G, Sood A, Ozpolat B. Therapeutic targeting of Bcl-2 by systemically administred nanoliposomal siRNA inhibits tumor growth of ER(-) and ER(+) breast cancer xenografts by inducing authophagic and apoptotic cell death. Gene Therapy. Submitted. PMCID: PMCN/A.

Invited Articles

1. Hasmima N, Ozpolat B. Autophagy induction by polyphenolic compounds as a potential strategy in cancer therapy. Antimicrobial Agents and Chemotherapeutics. In Press.
2. Bircan A, Ozpolat B. EF2Kinase as novel therapeutic target in solid cancers. In Press.
3. Aslan B, Ozpolat B, Sood A, Lopez-Berestein G. Nanomedicine in Cancer. Journal Drug Targeting. In Press.
4. Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA Nanocarriers for Cancer Therapy. Adv Drug Deliv Rev 66C:110-116, 2/2014. e-Pub 12/30/2013. PMCID: PMC4527165.
5. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, Bamber BA, Bassham DC, Bergamini E, Bi X, Biard-Piechaczyk M, Blum JS, Bredesen DE, Brodsky JL, Brumell JH, Brunk UT, Bursch W, Camougrand N, Cebollero E, Cecconi F, Chen Y, Chin LS, Choi A, Chu CT, Chung J, Clarke PG, Clark RS, Clarke SG, Clavé C, Cleveland JL, Codogno P, Colombo MI, Coto-Montes A, Cregg JM, Cuervo AM, Debnath J, Demarchi F, Dennis PB, Dennis PA, Deretic V, Devenish RJ, Di Sano F, Dice JF, Difiglia M, Dinesh-Kumar S, Distelhorst CW, Djavaheri-Mergny M, Dorsey FC, Dröge W, Dron M, Dunn WA, Duszenko M, Eissa NT, Elazar Z, Esclatine A, Eskelinen EL, Fésüs L, Finley KD, Fuentes JM, Fueyo J, Fujisaki K, Galliot B, Gao FB, Gewirtz DA, Gibson SB, Gohla A, Goldberg AL, Gonzalez R, González-Estévez C, Gorski S, Gottlieb RA, Häussinger D, He YW, Heidenreich K, Hill JA, Hřyer-Hansen M, Hu X, Huang WP, Iwasaki A, Jäättelä M, Jackson WT, Jiang X, Jin S, Johansen T, Jung JU, Kadowaki M, Kang C, Kelekar A, Kessel DH, Kiel JA, Kim HP, Kimchi A, Kinsella TJ, Kiselyov K, Kitamoto K, Knecht E, Komatsu M, Kominami E, Kondo S, Kovács AL, Kroemer G, Kuan CY, Kumar R, Kundu M, Landry J, Laporte M, Le W, Lei HY, Lenardo MJ, Levine B, Lieberman A, Lim KL, Lin FC, Liou W, Liu LF, Lopez-Berestein G, López-Otín C, Lu B, Macleod KF, Malorni W, Martinet W, Matsuoka K, Mautner J, Meijer AJ, Meléndez A, Michels P, Miotto G, Mistiaen WP, Mizushima N, Mograbi B, Monastyrska I, Moore MN, Moreira PI, Moriyasu Y, Motyl T, Münz C, Murphy LO, Naqvi NI, Neufeld TP, Nishino I, Nixon RA, Noda T, Nürnberg B, Ogawa M, Oleinick NL,Olsen LJ,Ozpolat BPaglin S, Palmer GE, Papassideri I, Parkes M, Perlmutter DH, Perry G, Piacentini M, Pinkas-Kramarski R, Prescott M, Proikas-Cezanne T, Raben N, Rami A, Reggiori F, Rohrer B, Rubinsztein DC, Ryan KM, Sadoshima J, Sakagami H, Sakai Y, Sandri M, Sasakawa C, Sass M, Schneider C, Seglen PO, Seleverstov O, Settleman J, Shacka JJ, Shapiro. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4(2):151-75, 2/2008. e-Pub 11/2007. PMCID: PMC2654259.

Grant & Contract Support

Title: Targeting Kras in Pancreatic Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 7/1/2015 - 6/30/2017
Title: Development of novel drugs for prostate cancer therapy
Funding Source: Universiy of Oslo
Role: Principal Investigator
Duration: 1/1/2015 - 12/31/2017
Title: Highly Specific Targeting of the TMPRSS2/ERG Fusion Gene in Prostate Cancer
Funding Source: Veterans Administration
Role: Principal Investigator
Duration: 10/1/2014 - 9/30/2018
Title: (PDQ3) The role and therapeutic potential of ZNF304 in ovarian cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2014 - 8/31/2015
Title: Multistage Vectors (MSV) for Ovarian Cancer Therapeutics
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Gorenstein, Sood, Ferrari, Lopez, Mitra
Duration: 8/1/2013 - 7/31/2015

Last updated: 12/10/2015